Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To determine whether platelet-rich-plasma (PRP) or HA (hyaluronic acid)injection into synovitis in osteoarthritis(OA) knee can achieve improvement in knee function and reduce synovitis.
Methods:
sixty patients with OA knee having unilateral or bilateral synovitis validated by ultrasound (N=40) were studied. All the patients were randomized to receive PRP (N=40) or Hyaluronic acid(HA)(N=40) injection twice at 2-week intervals; Clinical assessments were performed using a visual analog scale(VAS) and The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC index) before injection at baseline, 4 weeks(first evaluation) and 12 weeks(secondary evaluation). Imaging evaluation based on color Doppler ultrasound(CDUS) and the depth of synovial fluid accumulation ,and the width of synovial hypertrophy was performed simultaneously.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PRP group | Experimental | the patients received PRP(platelet-rich-plasma) injection twice at 2-week intervals |
|
| HA group | Active Comparator | the patients received HA(hyaluronic acid) injection twice at 2-week intervals |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| platelet rich plasma | Drug | The amount of PPR was about 4-5 cc |
| |
| Measure | Description | Time Frame |
|---|---|---|
| visual analog scale(VAS) | before injection at baseline | |
| visual analog scale(VAS) | 4 weeks(first evaluation) | |
| visual analog scale(VAS) | 12 weeks(secondary evaluation) | |
| The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC index) | before injection at baseline | |
| The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC index) | 4 weeks(first evaluation) | |
| The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC index) | 12 weeks(secondary evaluation) |
| Measure | Description | Time Frame |
|---|---|---|
| Imaging evaluation based on color Doppler ultrasound(CDUS) and the depth of synovial fluid accumulation ,and the width of synovial hypertrophy was performed simultaneously. | before injection at baseline | |
| Imaging evaluation based on color Doppler ultrasound(CDUS) and the depth of synovial fluid accumulation ,and the width of synovial hypertrophy was performed |
Not provided
Inclusion Criteria:
diagnosed with OA knee according to ACR guideline
Exclusion Criteria:
1. OA knee secondary to other disease 2 . more than 10 years after diagnosing OA 3. under knee surgery within 3 months 4. autoimmune disease 5. refuses inform/consent process
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Chien-CHIh Wang, MD | Contact | 886-958738258 | candycandywang@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Taipei veteran general hospital yuli branch | Recruiting | Hualien City | 886 | Taiwan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020370 | Osteoarthritis, Knee |
| ID | Term |
|---|---|
| D010003 | Osteoarthritis |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D006820 | Hyaluronic Acid |
| ID | Term |
|---|---|
| D006025 | Glycosaminoglycans |
| D011134 | Polysaccharides |
| D002241 | Carbohydrates |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Hyaluronic acid |
| Drug |
HA was 2.5cc |
|
| 4 weeks(first evaluation) |
| Imaging evaluation based on color Doppler ultrasound(CDUS) and the depth of synovial fluid accumulation ,and the width of synovial hypertrophy was performed | 12 weeks(secondary evaluation) |
| D012216 |
| Rheumatic Diseases |